EGFR and colorectal carcinoma: Standard first-line pharmacological treatments against CRC are chemotherapy regimens like FOLFOX (folinic acid, 5-fluorouracil (5-FU), and oxaliplatin) or FOLFIRI (folinic acid, 5-FU, and irinotecan) in combination with monoclonal antibodies against growth factors or RTK such as VEGF-A (vascular endothelial growth factor A), e.g. bevacizumab, and EGFR (epidermal growth factor receptor), e.g. cetuximab or panitumumab [92].